THE DEADLINE TO FILE A CLAIM HAS PASSED.

A partial settlement has been reached in a class action lawsuit involving the antiretroviral drugs Atripla, Biktarvy, Complera, Descovy, Evotazz, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread (the "Settlement").

The lawsuit claims that Gilead Sciences, Inc., Gilead Holdings, LLC, Gilead Sciences, LLC, and Gilead Sciences Ireland UC ("Gilead"), Bristol-Myers Squibb Company and E. R. Squibb & Sons, L.L.C. ("BMS"), and Johnson & Johnson, Janssen Products LP, and Janssen R&D Ireland ("Janssen") (collectively, "Defendants") engaged in a variety of allegedly anticompetitive conduct that caused certain consumers and third-party payors (the "End-Payor Class") to pay too much for HIV medicines, specifically: Atripla, Biktarvy, Complera, Descovy, Evotaz, Genvoya, Odefsey, Prezcobix, Stribild, Symtuza, Truvada, and Viread. Defendants deny any wrongdoing. For additional details and answers to frequently asked questions, please read the Long-Form Notice.

If you are a consumer member of the Atripla Settlement Damages Class or the Evotaz Settlement Damages Class you may file a claim now. If you are a TPP member of a Settlement Damages Class, you will be notified when to submit a Claim Form. Payments to eligible consumers of Atripla and Evotaz will vary based on the number of claims, but are expected to average $70.50 to $282.

Generally, you are included in the Atripla Settlement Damages Class if you reside in the United States or its territories and you purchased, paid, and/or provided reimbursement in (which shall include, with respect to TPPs, the state in which you have your principal place of business) any of the Damages States for some or all of the purchase price for brand or generic Atripla, sold by Bristol-Myers Squibb Company or its affiliates, by Gilead Sciences, Inc. or its affiliates, or by Teva Pharmaceutical Industries Ltd. or its affiliates, for consumption by yourself or your family, or, with respect to TPPs, by your members, employees, insureds, participants, citizens, residents, or beneficiaries, other than for resale, during the period May 14, 2015, through and until October 13, 2021. The Atripla Settlement Damages Class includes Third-Party Payors (“TPPs”) and individual consumers.

Generally, you are included in the Evotaz Settlement Damages Class if you reside in the United States or its territories and you purchased, paid, and/or provided reimbursement in (which shall include, with respect to TPPs, the state in which you have your principal place of business) any of the Damages States for some or all of the purchase price of Evotaz, for consumption by yourself or your family, or, with respect to TPPs, by your members, employees, insureds, participants, citizens, residents, or beneficiaries, other than for resale, during the period May 14, 2015, through and until October 13, 2021. The Evotaz Settlement Damages Class includes TPPs and individual consumers.